The PROMUS Stent expands Boston Scientific's drug-eluting stent portfolio, which includes the TAXUS® Express2® Paclitaxel-Eluting Coronary Stent System and the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System, making Boston Scientific the only company to offer physicians the choice of two distinct drugs (paclitaxel and everolimus) on separate DES platforms.
Ted Feldman, M.D., F.S.C.A.I., Director of the Cardiac Catheterization Laboratory at Evanston Northwestern Healthcare in Evanston, Illinois said, The PROMUS Stent has shown outstanding deliverability, low late loss and the potential to reduce the need for re-interventions. These benefits will make the PROMUS Stent an attractive new treatment option for U.S. physicians and their patients
Jim Tobin, President and Chief Executive Officer of Boston Scientific said, FDA approval of the PROMUS Stent fulfills Boston Scientific's promise of an unprecedented two-drug strategy – two distinct drugs on two highly deliverable stent platforms. The PROMUS Stent complements our broad DES portfolio and further reinforces Boston Scientific's leadership in the DES market, as well as our commitment to continued innovation and improved patient outcomes
Boston Scientific's PROMUS Stent and Abbott's XIENCE V Stent are identical products sold by the respective companies under different brand names. The PROMUS (XIENCE V) Stent is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.0 mm.